摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

盐酸磷奈妥匹坦* | 1643757-72-5

中文名称
盐酸磷奈妥匹坦*
中文别名
——
英文名称
4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium chloride hydrochloride
英文别名
Fosnetupitant chloride;[4-[5-[[2-[3,5-bis(trifluoromethyl)phenyl]-2-methylpropanoyl]-methylamino]-4-(2-methylphenyl)pyridin-2-yl]-1-methylpiperazin-1-ium-1-yl]methyl dihydrogen phosphate;chloride;hydrochloride
盐酸磷奈妥匹坦*化学式
CAS
1643757-72-5
化学式
C31H36F6N4O5P*ClH*Cl
mdl
——
分子量
761.529
InChiKey
LBTQUZNIWCWBNN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.79
  • 重原子数:
    49
  • 可旋转键数:
    8
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.42
  • 拓扑面积:
    103
  • 氢给体数:
    3
  • 氢受体数:
    14

制备方法与用途

氯化氯是一盐酸盐促吐剂,是一种NK1拮抗剂,对人NK1和NK3受体的pKi值分别为9.5和6.1。它实际上是耐图坦的亚甲基磷酸前药。

反应信息

点击查看最新优质反应信息

文献信息

  • 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium as a neurokinin receptor modulator
    申请人:HELSINN HEALTHCARE SA
    公开号:US09403772B2
    公开(公告)日:2016-08-02
    Compounds and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the neurokinin (NK1) receptor, based on 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)3yridine-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium and pharmaceutically acceptable salts thereof.
    基于4-(5-(2-(3,5-二(三氟甲基)苯基)-N,2-二甲基丙酰胺)-4-(邻甲苯基)3yridine-2-基)-1-甲基-1-((磷酸氧基)甲基)哌嗪-1-离子的化合物及其药用盐,用于预防或治疗由神经激肽(NK1)受体介导的疾病。
  • PROCESS FOR PREPARATION OF FOSNETUPITANT
    申请人:CADILA HEALTHCARE LIMITED
    公开号:US20210214306A1
    公开(公告)日:2021-07-15
    The present invention relates to a process for the preparation of fosnetupitant. The invention further relates to an amorphous fosnetupitant chloride hydrochloride and process for the preparation thereof.
    本发明涉及一种制备福斯奈托匹坦的方法。该发明还涉及一种非晶态福斯奈托匹坦盐酸盐和其制备方法。
  • SUBSTITUTED 4-PHENYL-PYRIDINES
    申请人:HELSINN HEALTHCARE SA
    公开号:US20150011510A1
    公开(公告)日:2015-01-08
    Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the neurokinin (NK 1 ) receptor. The compounds have the general formula (I):
    本发明涉及一种化合物、组合物和方法,用于预防和/或治疗由神经激肽(NK1)受体病理生理介导的疾病。该化合物具有一般式(I):
  • Substituted 4-Phenyl Pyridines
    申请人:Helsinn Healthcare SA
    公开号:US20170050993A1
    公开(公告)日:2017-02-23
    Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the neurokinin (NK 1 ) receptor. The compounds have the general formula (I):
    本发明涉及以下通式(I)的化合物、组合物和方法,用于预防和/或治疗由神经激肽(NK1)受体病理生理介导的疾病。
  • Solution comprising the chloride hydrochloride salt of 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-IUM-(fosnetupitant) and palonosetron hydrochloride in combination with dexamethasone as a neurokinin receptor modulator
    申请人:HELSINN HEALTHCARE SA
    公开号:US10208073B2
    公开(公告)日:2019-02-19
    Disclosed is a solution comprising the chloride hydrochloride salt of 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium (fosnetupitant) and palonosetron hydrochloride in combination with dexamethasone and its application in methods for preventing acute and delayed nausea and vomiting in a human patient receiving highly emetogenic cancer chemotherapy.
    本发明公开了一种包含 4-(5-(2-(3,5-双(三氟甲基)苯基)-N、2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium (fosnetupitant) 和盐酸帕洛诺司琼(palonosetron hydrochloride)与地塞米松(dexamethasone)的盐酸盐组成的溶液,以及该溶液在预防接受高致吐性癌症化疗的人类患者的急性和迟发性恶心和呕吐中的应用。
查看更多